Boehringer Ingelheim International Gmbh

Vertex Pharmaceuticals, Inc.

Shire Biochem, Inc.

Shire Canada Inc.

Jean-Eric Lacoste

Claudio F Sturino

Pierre Louis Beaulieu

Martin Duplessis

Clint A James

Patrick Deroy

Martin Tremblay

Louis Morency

Joannie Minville

Luc J Farmer

Christiane Yoakim

Jean Rancourt

Bruno Simoneau

Teddy Halmos

Anne-Marie Faucher

Elisia Villemure

Yeeman K Ramtohul

Carl Thibeault

Constantin G Yannopoulos

Paul John Edwards

Bingcan Liu

Monica Bubenik

Simon Surprenant

Melissa Leblanc

Chantal Grand-Maitre

Sebastien Morin

Frederic Vallee

Dragos Vizitiu

Eric Jolicoeur

Julien Martel

Oliver Hucke

Eric Malenfant

Cyrille Kuhn

Janek Szychowski

Stephanie Lessard

Ioana R Simion, Legal Representative

Miguel St-Onge

Sébastien Morin

Anne Décor

Pierre-Andre Fournier

Camil Elie Sayegh

Dan Simion

Paul J Edwards

Pierre L Beaulieu

Anne DÉCOR

Claudio Sturino

The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.

Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Compounds of Formula (I) wherein R, R, R, R, Y, Zand Zare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

Compounds of formula (I) and pharmaceutical compositions thereof: wherein AAand Aare each independently selected from the group consisting of N and CR, wherein Ris an optionally substituted heterocyclyl or an optionally substituted &#x2014;(C)alkyl-heterocyclyl, Ris an optionally substituted aryl or an optionally subsisted heteroaryl, Ris an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication. 

Inhibitors of HIV replication

Compounds of formula (I): wherein R, R, A, A, A, A, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Single enantionmers of compounds of formula (B), in either the cis or trans configuration, wherein Rand Rare as defined herein, can be separated from enantiomeric mixtures thereof by reacting the compound with an acid to produce a conglomerate salt that has the following characteristics:

Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides

Growing community of inventors

Laval, Canada

Jean-Eric Lacoste